Citigroup’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.04K | Buy |
495
+257
| +108% | +$1.83K | ﹤0.01% | 5362 |
|
|
2025
Q4 | $1.72K | Sell |
238
-429
| -64% | -$3.47K | ﹤0.01% | 5474 |
|
|
2025
Q3 | $6.82K | Sell |
667
-2,962
| -82% | -$33.3K | ﹤0.01% | 5133 |
|
|
2025
Q2 | $37.7K | Sell |
3,629
-4,079
| -53% | -$43.4K | ﹤0.01% | 4903 |
|
|
2025
Q1 | $102K | Sell |
7,708
-543
| -7% | -$9.7K | ﹤0.01% | 4591 |
|
|
2024
Q4 | $148K | Buy |
8,251
+3,034
| +58% | +$61.4K | ﹤0.01% | 4620 |
|
|
2024
Q3 | $84.1K | Buy |
5,217
+3,645
| +232% | +$57K | ﹤0.01% | 4847 |
|
|
2024
Q2 | $42.5K | Buy |
1,572
+845
| +116% | +$20.2K | ﹤0.01% | 4680 |
|
|
2024
Q1 | $14.2K | Buy |
727
+82
| +13% | +$1.74K | ﹤0.01% | 5122 |
|
|
2023
Q4 | $13.3K | Buy |
645
+584
| +957% | +$17.4K | ﹤0.01% | 5122 |
|
|
2023
Q3 | $1.94K | Sell |
61
-1,179
| -95% | -$39.4K | ﹤0.01% | 4966 |
|
|
2023
Q2 | $41.6K | Sell |
1,240
-5,122
| -81% | -$183K | ﹤0.01% | 4734 |
|
|
2023
Q1 | $265K | Sell |
6,362
-3,760
| -37% | -$177K | ﹤0.01% | 3561 |
|
|
2022
Q4 | $343K | Buy |
10,122
+9,660
| +2,091% | +$411K | ﹤0.01% | 3416 |
|
|
2022
Q3 | $23K | Buy |
462
+257
| +125% | +$14.1K | ﹤0.01% | 4695 |
|
|
2022
Q2 | $8K | Sell |
205
-71
| -26% | -$2.1K | ﹤0.01% | 5458 |
|
|
2022
Q1 | $10K | Sell |
276
-641
| -70% | -$40.1K | ﹤0.01% | 5544 |
|
|
2021
Q4 | $90K | Sell |
917
-2,833
| -76% | -$305K | ﹤0.01% | 4784 |
|
|
2021
Q3 | $468K | Buy |
3,750
+3,353
| +845% | +$405K | ﹤0.01% | 3664 |
|
|
2021
Q2 | $50K | Sell |
397
-4,214
| -91% | -$502K | ﹤0.01% | 4826 |
|
|
2021
Q1 | $626K | Buy |
4,611
+4,044
| +713% | +$502K | ﹤0.01% | 3304 |
|
|
2020
Q4 | $52K | Buy |
567
+432
| +320% | +$37.5K | ﹤0.01% | 6016 |
|
|
2020
Q3 | $10K | Sell |
135
-193
| -59% | -$14.8K | ﹤0.01% | 6638 |
|
|
2020
Q2 | $28K | Sell |
328
-5,080
| -94% | -$460K | ﹤0.01% | 6369 |
|
|
2020
Q1 | $391K | Buy |
5,408
+5,381
| +19,930% | +$520K | ﹤0.01% | 4100 |
|
|
2019
Q4 | $2K | Sell |
27
-67
| -71% | -$3.23K | ﹤0.01% | 7559 |
|
|
2019
Q3 | $5K | Sell |
94
-211
| -69% | -$11.2K | ﹤0.01% | 7346 |
|
|
2019
Q2 | $16K | Sell |
305
-54
| -15% | -$3.68K | ﹤0.01% | 7164 |
|
|
2019
Q1 | $25K | Buy |
359
+167
| +87% | +$10.6K | ﹤0.01% | 6839 |
|
|
2018
Q4 | $16K | Buy |
192
+17
| +10% | +$3.88K | ﹤0.01% | 6981 |
|
|
2018
Q3 | $82K | Buy |
175
+165
| +1,650% | +$66.3K | ﹤0.01% | 6083 |
|
|
2018
Q2 | $4K | Sell |
10
-71
| -88% | -$25.2K | ﹤0.01% | 7391 |
|
|
2018
Q1 | $24K | Buy |
81
+77
| +1,925% | +$21.9K | ﹤0.01% | 6649 |
|
|
2017
Q4 | $1K | Buy |
+4
| New | +$1.75K | ﹤0.01% | 7492 |
|
|
2017
Q3 | – | Sell |
-4
| Closed | -$3K | – | 7408 |
|
|
2017
Q2 | $3K | Sell |
4
-3
| -43% | -$1.32K | ﹤0.01% | 6900 |
|
|
2017
Q1 | $3K | Buy |
+7
| New | +$2.94K | ﹤0.01% | 6938 |
|
|
2016
Q4 | – | Sell |
-14
| Closed | -$8.18K | – | 7301 |
|
|
2016
Q3 | $6K | Buy |
+14
| New | +$5.47K | ﹤0.01% | 6723 |
|
Other funds holding RNAC
VCM
6CM
EAM
Citigroup's RNAC Position: Q1 2026 in Review
Citigroup increased its Cartesian Therapeutics (RNAC) stake by 108% in Q1 2026, buying an estimated $1.83K and bringing the position to 495 shares worth $3.04K. The position accounts for ﹤0.01% of the portfolio, ranked #5362.
Citigroup first reported a position in RNAC in Q3 2016 and has held it in 37 quarters since. The position peaked at $626K in Q1 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.
- Citigroup held 495 shares of Cartesian Therapeutics worth $3.04K as of Q1 2026.
- Citigroup bought 257 Cartesian Therapeutics shares in Q1 2026, an estimated $1.83K.
- Cartesian Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5362 holding.
- Citigroup first reported a position in Cartesian Therapeutics in Q3 2016 and has held it in 37 quarters since.
- Citigroup's Cartesian Therapeutics position peaked at $626K in Q1 2021.
- 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.